Gene and cell therapy boom drives DNA manufacturing market toward $21.82B by 2034

Biotech investments fuel DNA manufacturing in Asia-Pacific.

The global DNA manufacturing market is projected to reach $21.82b by 2034, with a compound annual growth rate of 14.62%, according to Polaris Market Research.

The Asia-Pacific region is experiencing rapid growth through biotechnology investments in China, Japan, South Korea, and India.

North America represented 47.38% of global revenue in 2024, with the United States leading the region through research funding and regulatory support for genetic technologies. Europe maintains market activity through pharmaceutical research and the Horizon Europe programme.

Investment in gene and cell therapies for oncology and regenerative medicine drives market demand, as synthetic DNA holds the largest market share due to its use in research and synthetic biology platforms.

Requirements for Good Manufacturing Practice grade DNA for clinical applications also influence growth. Artificial intelligence tools optimise gene constructs and synthesis timelines.

The cell and gene therapy segment generated the largest revenue share in 2024. End users include pharmaceutical companies, biotechnology firms, academic institutions, and contract research organisations (CROs).

CROs provide manufacturing services and specialised expertise to reduce time to market for DNA-based products.